Current Medical Science

, Volume 37, Issue 5, pp 693–698 | Cite as

Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

  • Jie-ke Cui (崔杰克)
  • Yin Xiao (肖 音)
  • Yong You (游 泳)
  • Wei Shi (石 威)
  • Qing Li (李 青)
  • Yi Luo (罗 毅)
  • Lin Jiang (蒋 林)
  • Zhao-dong Zhong (仲照东)Email author


Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a main question on treatment failure. Current strategies for management that usually include salvage chemotherapy, donor lymphocytic infusion and second transplantation. Our study assessed the efficacy of decitabine (DAC) for treating patients with acute lymphoblastic leukemia (ALL) who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed the outcomes of 12 patients with relapsed ALL after allo-HSCT who received DAC therapy. Nine patients received DAC combined with chemotherapy and donor stem cell infusion, and 3 patients received single- agent DAC. Ten of the 12 patients achieved complete remission (CR), 1 achieved a partial remission (PR), and 1 had no response (NR) after treatment at the latest follow-up (LFU), the median survival was 11.2 months (range, 3.8–34, 7 months). The 1- and 2-year overall survival (OS) rates were 50% (6/12) and 25% (3/12), respectively. Five patients were still alive; 4 had maintained CR and 1 was alive with disease. Patients with Philadelphia chromosome-positive ALL had higher survival rate than patients with Philadelphia chromosome-negative ALL (57.1% vs. 20%). No aggravated flares of graft-versus-host disease (GVHD) were observed during DAC treatment. Therefore, DAC may be a promising therapeutic agent for ALL recurrence after allo-HSCT.

Key words

decitabine acute lymphoblastic leukemia (ALL) allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008,111(4):1827–1833CrossRefPubMedGoogle Scholar
  2. 2.
    Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 2012,120(10): 2032–2041CrossRefPubMedGoogle Scholar
  3. 3.
    Andreola G, Labopin M, Beelen D, et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years. Bone Marrow Transplant, 2015,50(12):1508–1512CrossRefPubMedGoogle Scholar
  4. 4.
    Jabbour E, Issa JP, Garcia-Manero G, et al. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer, 2008,112(11): 2341–2351CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist, 2013,18(5): 619–624CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schubeler D. Function and information content of DNA methylation. Nature, 2015,517(7534):321–326CrossRefPubMedGoogle Scholar
  7. 7.
    Kim DY, Lee JH, Park YH, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant, 2012,47(3):374–379CrossRefPubMedGoogle Scholar
  8. 8.
    de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer, 2010,116(23):5420–5431CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood, 2010,116(1):129–139CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tessoulin B, Delaunay J, Chevallier P, et al. Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone Marrow Transplant, 2014,49(4):567–571CrossRefPubMedGoogle Scholar
  11. 11.
    Nie DM, Wu QL, Zhu XX, et al. Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. J Huazhong Univ Sci Technolog Med Sci, 2015,35(5):694–699CrossRefPubMedGoogle Scholar
  12. 12.
    Zhong ZD, Li L, Wu YH, et al. Analysis of seizure risk factors after allogeneic hematopoietic stem cell transplantation: a 8-case report and literature review. J Huazhong Univ Sci Technolog Med Sci, 2013,33(5): 656–660CrossRefPubMedGoogle Scholar
  13. 13.
    Cairo MS, Jordan CT, Maley CC, et al. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant, 2010,16(6):709–728CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant, 2015,21(3):389–401.e381Google Scholar
  15. 15.
    Poon LM, Hamdi A, Saliba R, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2013,19(7):1059–1064CrossRefPubMedGoogle Scholar
  16. 16.
    Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia, 2012,26(6):1211–1217Google Scholar
  17. 17.
    Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer, 2009,115(9):1899–1905CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ravandi F, Kantarjian H, Cohen A, et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant, 2001,27(12):1221–1225CrossRefPubMedGoogle Scholar
  19. 19.
    Liesveld JL, O'Dwyer K, Walker A, et al. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res, 2013,37(12):1622–1627CrossRefPubMedGoogle Scholar
  20. 20.
    Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica, 2012,97(3):393–401CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Van der Meulen J, Van Roy N, Van Vlierberghe P, et al. The epigenetic landscape of T-cell acute lymphoblastic leukemia. Int J Biochem Cell Biol, 2014,53:547–557CrossRefPubMedGoogle Scholar
  22. 22.
    Qian J, Wang YL, Lin J, et al. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia. Eur J Haematol, 2009,82(2): 119–123CrossRefPubMedGoogle Scholar
  23. 23.
    Pehlivan M, Sercan Z, Sercan HO. sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk Res, 2009,33(8):1062–1067CrossRefPubMedGoogle Scholar
  24. 24.
    Ganguly S, Amin M, Divine C, et al. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). Ann Hematol, 2013,92(4):549–550CrossRefPubMedGoogle Scholar
  25. 25.
    Lu BY, Thanawala SU, Zochowski KC, et al. Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leuk Lymphoma, 2016,57(8):1938–1941CrossRefPubMedGoogle Scholar
  26. 26.
    Giralt S, Davis M, O'Brien S, et al. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia, 1997,11 (Suppl 1):S32–34PubMedGoogle Scholar
  27. 27.
    Remberger M, Torlen J, Ringden O, et al. Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2015,21(5):889–893CrossRefPubMedGoogle Scholar
  28. 28.
    Rambaldi A, Viero P, Bassan R, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. Leukemia, 1996,10(5):860–865PubMedGoogle Scholar
  29. 29.
    Hambach L, Ling KW, Pool J, et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood, 2009,113(12): 2715–2722CrossRefPubMedGoogle Scholar
  30. 30.
    Engel N, Rank A. Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics, 2011,3(5):611–623CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Jie-ke Cui (崔杰克)
    • 1
  • Yin Xiao (肖 音)
    • 2
  • Yong You (游 泳)
    • 1
  • Wei Shi (石 威)
    • 1
  • Qing Li (李 青)
    • 1
  • Yi Luo (罗 毅)
    • 3
  • Lin Jiang (蒋 林)
    • 1
  • Zhao-dong Zhong (仲照东)
    • 1
    Email author
  1. 1.Institute of Hematology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Cancer Center, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Department of Hematology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations